#1 Clinical Trials Search in Europe

Grwd5769

GRWD5769 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors. This article provides an overview of the ongoing research, focusing on the safety, tolerability, and potential effectiveness of GRWD5769 when used alone or in combination with other cancer treatments. The trials aim to determine the optimal dosage and evaluate the drug’s impact on various types of solid malignancies, offering hope for patients with limited treatment options.

Table of Contents

What is GRWD5769?

GRWD5769 is a new drug being developed by Grey Wolf Therapeutics Limited for the treatment of advanced solid tumors[1]. It is currently being studied in clinical trials to evaluate its safety and effectiveness in cancer patients. GRWD5769 is taken orally in the form of a capsule[1].

How does GRWD5769 work?

GRWD5769 is an ERAP1 inhibitor. ERAP1 stands for Endoplasmic Reticulum Aminopeptidase 1, which is an enzyme involved in processing proteins in cells. By inhibiting ERAP1, GRWD5769 may help the immune system better recognize and attack cancer cells[1]. This makes it a type of immunotherapy, which are treatments that work with your body’s immune system to fight cancer.

What conditions does GRWD5769 treat?

GRWD5769 is being studied for the treatment of advanced solid tumors. Solid tumors are abnormal masses of tissue that don’t contain cysts or liquid areas. They may occur in many parts of the body, such as the breast, lung, prostate, and other organs. “Advanced” typically means that the cancer has spread from where it started to other parts of the body[1].

Specific types of cancer being studied include:

  • Non-small cell lung cancer (NSCLC)
  • Urothelial cancer (cancer of the bladder and urinary tract)
  • Head and neck squamous cell carcinoma (SCCHN)
  • Gastric (stomach) and gastro-esophageal cancer
  • Esophageal squamous cell carcinoma
  • Cervical cancer
  • Hepatocellular carcinoma (liver cancer)

Current Research on GRWD5769

GRWD5769 is currently being studied in a clinical trial called a “Phase I/II study”[1]. This type of study is designed to:

  1. Determine the safety and tolerability of GRWD5769
  2. Find the right dose of the drug
  3. See how well it works against cancer

The study is testing GRWD5769 both alone and in combination with another drug called cemiplimab (Libtayo®). Cemiplimab is an approved immunotherapy drug that works differently from GRWD5769[1].

Potential Benefits of GRWD5769

While it’s too early to know for sure, researchers hope that GRWD5769 might offer several potential benefits:

  • It may help treat cancers that have stopped responding to other immunotherapies
  • It could potentially work against multiple types of solid tumors
  • Being an oral medication, it might be more convenient for patients than treatments given by injection or infusion

Who can participate in GRWD5769 trials?

The current trial is for adults (18 years or older) with advanced solid tumors who have already tried standard treatments or for whom no standard treatments are available[1]. Some key eligibility criteria include:

  • Having a confirmed diagnosis of an advanced solid tumor
  • Being in overall good health aside from the cancer
  • Having adequate organ function
  • For some parts of the study, having previously received and progressed on immunotherapy

There are also several factors that might prevent someone from participating, such as having certain other medical conditions or having received certain other treatments recently[1].

Safety and Side Effects

As GRWD5769 is still in early stages of testing, all of its potential side effects are not yet known. The current study is specifically designed to gather more information about the drug’s safety and side effects[1].

Patients in the study will be closely monitored for any adverse effects. Some general side effects that are often seen with cancer treatments and immunotherapies may include fatigue, nausea, and changes in blood cell counts. However, the specific side effects of GRWD5769 will become clearer as more research is conducted.

Future Prospects

If the current studies show promising results, GRWD5769 may move on to larger clinical trials. These would further test its effectiveness and safety in larger groups of patients. It’s important to remember that drug development is a long process, and it may be several years before we know if GRWD5769 will become an approved treatment[1].

For patients with advanced solid tumors, especially those who have exhausted other treatment options, the development of drugs like GRWD5769 represents hope for new and potentially effective treatments in the future.

Aspect Details
Drug Name GRWD5769
Administration Oral capsules
Trial Phase Phase I/II
Target Conditions Advanced solid tumors, including cervical cancer, hepatocellular carcinoma, and others
Main Objectives Assess safety, tolerability, optimal dosage, and preliminary efficacy
Study Design Multi-part, multi-arm, open-label study
Combination Therapy Tested alone and in combination with cemiplimab (Libtayo®)
Key Eligibility Criteria Adults with confirmed advanced solid tumors, limited standard treatment options, ECOG status 0-1
Primary Endpoints Incidence of adverse events, dose-limiting toxicities
Secondary Endpoints Maximum tolerated dose, recommended Phase 2 dose, pharmacokinetics, tumor response

FAQ

  • What is GRWD5769? GRWD5769 is an experimental drug being tested in clinical trials for the treatment of advanced solid tumors. It is designed to target specific mechanisms in cancer cells and is being studied both as a standalone treatment and in combination with other cancer therapies.
  • What types of cancer is GRWD5769 being tested for? GRWD5769 is being tested for various types of solid malignancies, including but not limited to advanced or metastatic solid tumors. Some specific cancer types mentioned in the trial include cervical cancer, hepatocellular carcinoma, and other solid tumors with moderate to high tumor mutation burden.
  • How is GRWD5769 administered? GRWD5769 is administered orally in the form of capsules. Patients in the trial are required to take the medication as directed and record their daily adherence to the study drug.
  • What are the main objectives of the clinical trials involving GRWD5769? The main objectives of the trials are to determine the safety and tolerability of GRWD5769 when used alone or in combination with other cancer treatments, to establish the optimal dosage, and to assess its preliminary effectiveness in treating solid tumors.
  • Who is eligible to participate in the GRWD5769 clinical trials? Eligibility criteria include adults (18 years or older) with confirmed advanced or metastatic solid tumors who have limited or no standard treatment options available. Participants must meet specific health criteria and be willing to comply with all study procedures. Some trials focus on patients who have previously received immunotherapy treatments.

Ongoing Clinical Trials on Grwd5769

  • Study on the Safety of GRWD5769 Alone and with Cemiplimab for Patients with Advanced Solid Tumors

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

Glossary

  • Solid malignancies: Cancers that form solid tumors in various parts of the body, such as organs or tissues, as opposed to blood cancers.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer patient responds to treatment.
  • iRECIST: A modified version of RECIST criteria specifically designed for assessing tumor response in cancer immunotherapy trials.
  • Checkpoint inhibitor (CPI): A type of immunotherapy drug that helps the immune system recognize and attack cancer cells.
  • MTD: Maximum Tolerated Dose – the highest dose of a drug that can be given without causing unacceptable side effects.
  • RP2D: Recommended Phase 2 Dose – the optimal dose of a drug determined for further testing in larger clinical trials.
  • PK (Pharmacokinetics): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • DLT (Dose-Limiting Toxicity): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • MBAD: Minimum Biologically Active Dose – the lowest dose of a drug that produces a measurable biological effect.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-grwd5769-alone-and-with-cemiplimab-for-patients-with-advanced-solid-tumors/